Brean Murray Carret maintains its Hold rating on Onyx ONXX as Phase III data on the CORRECT trial is released.
Brean Murray Carret notes, "Onyx and Bayer released Phase 3 data from the CORRECT trial (in an abstract from ASCO GI) where 760 patients who had previously failed standard therapy for metastatic
colorectal cancer (mCRC) were randomized 2:1 to either regorafenib or placebo. ...The progression free
survival (PFS) was 1.9 months for regorafenib patients versus 1.7 months for the placebo
patients, and the overall response rate was not statistically significant. ...We are not particularly encouraged by the OS or PFS data, especially given how Onyx shares have responded so positively to the Bayer renegotiation."
ONXX closed at $43.86 per share on Tuesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in